Jogendran Manisha, Flemming Jennifer A
Department of Medicine, Queen's University, Kingston, Ontario, Canada.
Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.
Can Liver J. 2024 Feb 22;7(3):368-376. doi: 10.3138/canlivj-2023-0031. eCollection 2024 Aug.
The incidence of gynecological and breast cancers is on the rise in addition to a rise in the incidence of cirrhosis among women. Women with cirrhosis are generally excluded from clinical trials therefore little is known about the oncologic and/or liver-related outcomes in this population. The aim of this study was to review the current literature regarding treatment and survival outcomes in females with gynecological or breast cancer with underlying cirrhosis.
An electronic search was conducted for studies reporting outcomes among females with cirrhosis and gynecological and breast cancer. References were reviewed for relevant publications. Studies were reviewed and data were extracted from publications.
Three thousand one hundred ninety one articles were identified, and five studies were reviewed in full. Thirty unique patients were identified. Ten patients with breast cancer were identified, 9/10 patients did not have cancer recurrence in the follow-up period, and 1/10 did not have follow up. 1/10 patient's received chemotherapy and developed degree II abnormal liver function and bone marrow suppression. 2/9 patients experienced postoperative complications, one had worsening thrombocytopenia and one developed mild encephalopathy. Nienteen patients with ovarian cancer all received surgery and chemotherapy. 10/19 had postoperative complications and 1/19 died in follow-up period. One patient had a neuroendocrine uterine cancer stage IV who died after one cycle of chemotherapy.
There is limited data on the outcomes and management of patients with both cirrhosis and gynecological or breast cancers. Therefore, further work is necessary to address these gaps in clinical practice to improve patient care.
除女性肝硬化发病率上升外，妇科和乳腺癌的发病率也在上升。肝硬化女性通常被排除在临床试验之外，因此对于该人群的肿瘤学和/或肝脏相关结局知之甚少。本研究的目的是回顾当前关于患有潜在肝硬化的妇科或乳腺癌女性的治疗和生存结局的文献。
对报告肝硬化合并妇科和乳腺癌女性结局的研究进行电子检索。查阅参考文献以获取相关出版物。对研究进行综述并从出版物中提取数据。
共识别出3191篇文章，对5项研究进行了全文综述。共识别出30例独特患者。识别出10例乳腺癌患者，10例中有9例在随访期间未出现癌症复发，1例未进行随访。1/10的患者接受化疗后出现II度肝功能异常和骨髓抑制。2/9的患者出现术后并发症，1例血小板减少症恶化，1例出现轻度脑病。19例卵巢癌患者均接受了手术和化疗。19例中有10例出现术后并发症，1/19在随访期间死亡。1例IV期神经内分泌子宫癌患者在一个化疗周期后死亡。
关于肝硬化合并妇科或乳腺癌患者的结局和管理的数据有限。因此，有必要进一步开展工作以填补临床实践中的这些空白，从而改善患者护理。
